| __timestamp | CRISPR Therapeutics AG | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 242549000 |
| Thursday, January 1, 2015 | 12573000 | 245098000 |
| Friday, January 1, 2016 | 42238000 | 147600000 |
| Sunday, January 1, 2017 | 69800000 | 264600000 |
| Monday, January 1, 2018 | 113773000 | 357900000 |
| Tuesday, January 1, 2019 | 179362000 | 1182600000 |
| Wednesday, January 1, 2020 | 266946000 | 357700000 |
| Friday, January 1, 2021 | 438633000 | 540100000 |
| Saturday, January 1, 2022 | 461645000 | 322900000 |
| Sunday, January 1, 2023 | 387332000 | 408000000 |
| Monday, January 1, 2024 | 320653000 |
Unleashing insights
In the ever-evolving world of biotechnology, research and development (R&D) expenses are a key indicator of a company's commitment to innovation. Over the past decade, United Therapeutics Corporation and CRISPR Therapeutics AG have demonstrated contrasting yet fascinating trends in their R&D investments.
United Therapeutics, a leader in the field, has consistently allocated substantial resources to R&D, peaking in 2019 with a remarkable 1.18 billion USD. This represents a nearly fivefold increase from their 2014 spending. Meanwhile, CRISPR Therapeutics, a pioneer in gene editing, has shown a meteoric rise in R&D expenses, growing from a modest 1.5 million USD in 2014 to an impressive 462 million USD in 2022.
These trends underscore the dynamic nature of the biotech industry, where strategic investments in R&D can drive groundbreaking advancements and shape the future of medicine.
R&D Insights: How Amgen Inc. and CRISPR Therapeutics AG Allocate Funds
GSK plc or CRISPR Therapeutics AG: Who Invests More in Innovation?
R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs United Therapeutics Corporation
United Therapeutics Corporation vs Exelixis, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: United Therapeutics Corporation vs Xenon Pharmaceuticals Inc.
United Therapeutics Corporation vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
United Therapeutics Corporation vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for United Therapeutics Corporation and Veracyte, Inc.
Research and Development Investment: Bio-Techne Corporation vs CRISPR Therapeutics AG
R&D Spending Showdown: Corcept Therapeutics Incorporated vs CRISPR Therapeutics AG
R&D Insights: How CRISPR Therapeutics AG and Soleno Therapeutics, Inc. Allocate Funds